Rapid decrease in tumor perfusion following VEGF blockade predicts long-term tumor growth inhibition in preclinical tumor models
Alexandra Eichten, Alexander P. Adler, Blerta Cooper et al. · Angiogenesis · 2012
Vascular endothelial growth factor (VEGF) is a key upstream mediator of tumor angiogenesis, and blockade of VEGF can inhibit tumor angiogenesis and decrease tumor growth. However, not all tumors respond well to anti-VEGF therapy. Despite much effort, identification of early response biomarkers that correlate with long-term efficacy of anti-VEGF therapy has been difficult. These difficulties arise in part because the functional effects of VEGF inhibition on tumor vessels are still unclear. We therefore assessed rapid molecular, morphologic and functional vascular responses following treatment with aflibercept (also known as VEGF Trap or ziv-aflibercept in the United States) in preclinical tumor models with a range of responses to anti-VEGF therapy, including Colo205 human colorectal carcinoma (highly sensitive), C6 rat glioblastoma (moderately sensitive), and HT1080 human fibrosarcoma (resistant), and correlated these changes to long-term tumor growth inhibition. We found that an overall decrease in tumor vessel perfusion, assessed by dynamic contrast-enhanced ultrasound (DCE-US), and increases in tumor hypoxia correlated well with long-term tumor growth inhibition, whereas changes in vascular gene expression and microvessel density did not. Our findings support previous clinical studies showing that decreased tumor perfusion after anti-VEGF therapy (measured by DCE-US) correlated with response. Thus, measuring tumor perfusion changes shortly after treatment with VEGF inhibitors, or possibly other anti-angiogenic therapies, may be useful to predict treatment efficacy.
Cited by 36 works. doi:10.1007/s10456-012-9328-3 Open-access PDF
Authors
- Alexandra Eichten
- Alexander P. Adler
- Blerta Cooper
- Yi Wei
- George D. Yancopoulos
- Hsin Chieh Lin
- Gavin Thurston
References
- Sorafenib in Advanced Hepatocellular Carcinoma
- Sorafenib in Advanced Hepatocellular Carcinoma
- Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
- Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
- A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib.
- Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
- Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma.
- Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma
- Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal
- Characterization of ICAM-2 and evidence for a third counter-receptor for LFA-1.